Form 4: PRECIGEN CEO Helen Sabzevari Granted 1 Million Stock Options
Insider Transaction Report
PRECIGEN, Inc.'s President and CEO, Helen Sabzevari, was granted 1 million stock options with an exercise price of $1.37, vesting over four years.
Summary
- Helen Sabzevari, the President and CEO of Precigen, Inc. (PGEN), acquired 1,000,000 stock options.
- The options have an exercise price of $1.37 per share.
- The options are set to expire on May 23, 2035.
- The vesting schedule for these options is 50% on May 23, 2026, with the remaining portion vesting in equal monthly installments over the subsequent three years.
Sentiment
Score: 7
Explanation: The grant of stock options to the CEO is generally viewed positively as it aligns management incentives with shareholder interests, encouraging long-term value creation. This is a standard compensation event for executives.
Positives
- The grant of 1,000,000 stock options to the President and CEO aligns management's interests with shareholder value creation.
- The long vesting period, extending until approximately May 23, 2029, incentivizes long-term performance and strategic decision-making.
Future Outlook
NA
Industry Context
This Form 4 filing is a standard disclosure of an insider equity grant and does not provide broader industry context or trends.
Stakeholder Impact
- Shareholders: Potential positive impact due to increased alignment of the CEO's interests with long-term shareholder value creation.
- Employees: No direct impact on general employees is mentioned in this filing.
Key Dates
| Date | Description |
|---|---|
| 05/23/2025 | Date of earliest transaction (grant of stock options) |
| 05/27/2025 | Date the Form 4 was signed by Helen Sabzevari's attorney-in-fact |
| 05/23/2026 | First vesting date for 50% of the granted options |
| 05/23/2029 | Approximate end of the vesting period for the remaining options (three years after the first vesting date) |
| 05/23/2035 | Expiration date of the stock options |
Keywords
Precigen, PGEN, Helen Sabzevari, stock options, insider transaction, Form 4, CEO compensation, equity grant
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.